- Recce Pharmaceuticals (RCE) secures sponsorship from the West Australian government to attend BIO Korea 2023
- RCE has been selected as one of three WA companies to attend the bio-health industry conference in Seoul this week
- The government’s sponsorship includes registration and participation fees, one-on-one meetings and VIP participation in networking events
- Recce says the event will provide important business opportunities including partnerships, government networking, clinical research collaborations and clinical trial expansion
- Recce Pharmaceuticals dips 1.52 per cent, trading at 65 cents at 11:55 am AEST.
Synthetic anti-infectives designer Recce Pharmaceuticals (RCE) has secured sponsorship from the West Australian government to attend BIO Korea 2023.
Recce was selected as one of three WA companies to attend the bio-health industry conference in Seoul from May 10 to May 12.
Last year, the conference drew in companies and attendees from over 50 countries, with over 22,400 on-site visitors.
Attendees include the world’s leading biotech companies, investors, executives, business experts and researchers.
The government’s sponsorship includes registration and participation fees, one-on-one meetings and VIP participation in networking events.
Recce said the event will provide important business opportunities including partnerships, government networking, clinical research collaborations, regulatory guidance, and clinical trial expansion.
The sponsorship follows Recce moving into its next phase of trials of its R327 antibiotics treatment for human use as an intravenous and topical therapy for treating serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria.
Recce Pharmaceuticals dipped 1.52 per cent, trading at 65 cents at 11:55 am AEST.